Friday, September 29, 2017 8:33:25 PM
Click For Filing
On September 29, 2017, SolarWindow Technologies, Inc. (the “ Company ”) entered into Subscription Agreements (each, a “ Subscription Agreement ”) with four investors (collectively, the “ Investors ”), for the purchase and sale of an aggregate of 821,600 units of the Company's equity securities (the “ Units ”) at a price of $3.11per Unit, pursuant to a private placement offering conducted by the Company (the “ Offering ”) for aggregate proceeds of $2,555,176.
The Unit price represents an approximately 15% discount to the 30-day average closing price of the Company's common stock as quoted on the OTC Markets QB tier for the 30 trading days prior to the Offering. Each Unit consists of: (i) one (1) share of common stock and (ii) one (1) Series S Stock Purchase Warrant to purchase one (1) share of common stock at a price of $3.42 per share through September 29, 2022 (the “ Series S Warrants ”); the Series S Warrants may be exercised on a cashless basis using the formula contained therein.
As part of the Offering, the Company and the Investors entered into a Registration Rights Agreement (the " Registration Rights Agreement ") requiring the Company to register for resale all of the shares of common stock sold as part of the Offering, including those issuable upon exercise of the Series S Warrants .
The Company intends to use the proceeds from the Offering to continue the development and commercialization efforts of its novel SolarWindow TM technology and for general corporate purposes.
Blessings to All
TRUTH
I've never claimed to have all the answers but feel i'm beginning to corner the market in questions worthy of them.
Recent WNDW News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 08:09:15 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/12/2024 08:48:19 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 11/21/2023 10:23:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/10/2023 08:25:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/10/2023 08:23:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/10/2023 08:21:19 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/30/2023 08:27:12 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM